Showing posts with label cardiovascular. Show all posts
Showing posts with label cardiovascular. Show all posts

Saturday, April 27, 2019

150-300 minutes physical activity offsets the harm from prolonged sitting


What bad food you eat may not matter, if you take enough amount of good food. And, if you sit for prolonged periods (6 or more hours daily), but replace the sitting time with exercise of at least moderate intensity, and with vigorous-intensity exercise, you can reduce the excess (CV) mortality risk.

The excess all-cause and CV mortality risks caused by regular, prolonged sitting is mainly seen in people who achieve less than 150 minutes of physical activity in a week. Those who maintain physical activity 150 to 200 minutes per week can considerably offset this excess risk; 300 minutes per week is even better.

It is not enough to replace sitting with standing. We need to be replacing sitting with movement. Even walking may do the trick in the case of all-cause mortality.

Some way outs

·    Increase physical activity to 150 to 299 min/week, or
·  Reduce sitting time from 8+ to <4 hours/day without increasing moderate to vigorous physical activity, or
· Increase moderate-to-vigorous physical activity to 150 to 299 min/week and reduce sitting to < 8 h/day.

Lesson: If you have to sit too much, make sure that you find ways to incorporate more moderate to vigorous physical activity into your life.

(Source: Journal of the American College of Cardiology, April 22)


Dr KK Aggarwal
Padma Shri Awardee
President Elect Confederation of Medical Associations in Asia and Oceania   (CMAAO)
Group Editor-in-Chief IJCP Publications
President Heart Care Foundation of India
Past National President IMA


Friday, August 5, 2011

#AskDrKK:What else can be tried in the treatment?


#DrKKAnswers: Additional therapies may include simple analgesics (paracetamol), bisphosphonates, nutritional supplements and cardiovascular risk reduction strategies.

Friday, July 22, 2011

Dr KK Answers: Can olmesartan prevent microalbuminuria in type 2 diabetes?


In type 2 diabetes (ROADMAP trial) patients assigned to receive olmesartan had significant reductions in systolic blood pressure and microalbuminuria but there was a significantly higher risk of cardiovascular death.
N Engl J Med 2011; 364:907

Thursday, July 21, 2011

Dr KK Answers: What should be the goal of diabetes control in patients with recent onset diabetes?


A review of results from recent clinical trials in patients with type 2 diabetes as well as extended follow-up of earlier trials has shown that that early and intensive anti diabetes treatment is recommended in patients with type 2 diabetics, particularly those with a shorter duration of disease and without a history of cardiovascular disease. The goal is to safely lower glycosylated hemoglobin to <7%.

Source: Clin Ther 2011 Jun; 33(6):665-78.